Welcome to the second installment in our video series highlighting the ways Cystic Fibrosis Foundation Therapeutics (CFFT) and industry are tackling cystic fibrosis from every angle. This week's topic explores the anti-inflammatory category in CFFT's drug development pipeline.
Dr. James Chmiel discusses new approaches to treat inflammation and explains why it is so important to address this issue. When people with CF develop lung infections, they tend to have an exaggerated inflammation response. This exaggerated response is responsible for much of the lung damage associated with CF and actually can be worse than the infection itself.
If you didn't catch our recent post on CFTR modulators, check it out here. And stay tuned for more videos about ongoing research.